LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 17, 2026-- AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted f…
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 17, 2026--
AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluatin…